LifeMD, Inc.

NasdaqGM:LFMD Voorraadrapport

Marktkapitalisatie: US$186.1m

LifeMD Inkomsten in het verleden

Verleden criteriumcontroles 0/6

LifeMD's earnings have been declining at an average annual rate of -10.8%, while the Healthcare Services industry saw earnings growing at 14% annually. Revenues have been growing at an average rate of 42.3% per year.

Belangrijke informatie

-10.8%

Groei van de winst

4.3%

Groei van de winst per aandeel

Healthcare Services Groei van de industrie1.7%
Inkomstengroei42.3%
Rendement op eigen vermogenn/a
Nettomarge-14.9%
Volgende winstupdate07 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

LifeMD: Are The Commons Too Cheap?

Sep 23

LifeMD: Selling WorkSimpli Could Be A Catalyst

Sep 10

It's Down 27% But LifeMD, Inc. (NASDAQ:LFMD) Could Be Riskier Than It Looks

Aug 16
It's Down 27% But LifeMD, Inc. (NASDAQ:LFMD) Could Be Riskier Than It Looks

LifeMD: High Growth GLP-1 Telehealth Play At A Discount

Jul 31

LifeMD: Pairing GLP-1 Agonists With Virtual Healthcare

Jun 11

LifeMD: Moving Towards Profitability

May 22

Is LifeMD (NASDAQ:LFMD) Using Debt Sensibly?

Apr 25
Is LifeMD (NASDAQ:LFMD) Using Debt Sensibly?

Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely

Mar 30
Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely

LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program

Mar 13

LifeMD's 2024: Striking A Balance Between Rapid Expansion And Sustainability

Jan 22

LifeMD: A GLP-1 Play With A Kicker

Jan 11

Is LifeMD, Inc. (NASDAQ:LFMD) Potentially Undervalued?

Jan 05
Is LifeMD, Inc. (NASDAQ:LFMD) Potentially Undervalued?

Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper

Jan 05
Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper

Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?

Dec 03
Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?

Investors Still Aren't Entirely Convinced By LifeMD, Inc.'s (NASDAQ:LFMD) Revenues Despite 38% Price Jump

Apr 17
Investors Still Aren't Entirely Convinced By LifeMD, Inc.'s (NASDAQ:LFMD) Revenues Despite 38% Price Jump

Analysts Are Betting On LifeMD, Inc. (NASDAQ:LFMD) With A Big Upgrade This Week

Nov 17
Analysts Are Betting On LifeMD, Inc. (NASDAQ:LFMD) With A Big Upgrade This Week

LifeMD launches at-home screening kits for breast, colon cancers

Sep 14

LifeMD Non-GAAP EPS of -$0.22 beats by $0.01, revenue of $30.5M misses by $1.45M

Aug 11

LifeMD CEO Justin Schreiber - Disrupting Healthcare With Telemedicine

Jan 10

Opbrengsten en kosten

Hoe LifeMD geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGM:LFMD Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 24178-271638
31 Mar 24164-261497
31 Dec 23153-241376
30 Sep 23136-321275
30 Jun 23129-331234
31 Mar 23123-391254
31 Dec 22119-491313
30 Sep 22118-551362
30 Jun 22112-611372
31 Mar 22104-641341
31 Dec 2193-621251
30 Sep 2178-751311
30 Jun 2164-851291
31 Mar 2151-731061
31 Dec 2037-63850
30 Sep 2028-32480
30 Jun 2020-9210
31 Mar 2014-5140
31 Dec 1912-3120
30 Sep 1911-3100
30 Jun 1910-3100
31 Mar 199-390
31 Dec 188-280
30 Sep 186-270
30 Jun 186-260
31 Mar 185-150
31 Dec 174-140
30 Sep 175-240
30 Jun 173-150
31 Mar 174-250
31 Dec 165-140
30 Sep 165-140
30 Jun 164020
31 Mar 163010
31 Dec 151010
30 Sep 151010
30 Jun 151010
31 Mar 151010
31 Dec 141010
30 Sep 141010
30 Jun 141010
31 Mar 141010
31 Dec 131010

Kwaliteitswinsten: LFMD is currently unprofitable.

Groeiende winstmarge: LFMD is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: LFMD is unprofitable, and losses have increased over the past 5 years at a rate of 10.8% per year.

Versnelling van de groei: Unable to compare LFMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: LFMD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (35.1%).


Rendement op eigen vermogen

Hoge ROE: LFMD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden